Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study.

被引：0
|
作者：
Garcia-Alfonso, Pilar
Munoz Martin, Andres J.
Jimenez-Castro, Jeronimo
Jimenez-Fonseca, Paula
Pericay, Carles
Longo, Federico
Reyna, Carmen
Argiles, Guillem
Gonzalez Astorga, Beatriz
Jose Gomez-Reina, Maria
Ruiz Casado, Ana
Rodriguez-Salas, Nuria
Lopez-Lopez, Rafael
Carmona Bayonas, Alberto
Conde-Herrero, Veronica
Aranda, Enrique
机构：
[1] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[2] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[3] Hosp Univ Virgen Rocio, Seville, Spain
[4] Hosp Univ Cent Asturias, Oviedo, Spain
[5] Hosp Sabadell, Corp Sanitaria Parc Tauli, Sabadell, Spain
[6] Inst Ramon & Cajal Invest Sanitaria IRICYS, Hosp Univ Ramon & Cajal, CIBERONC, Madrid, Spain
[7] Hosp Univ Reg & Virgen Victoria, Malaga, Spain
[8] Vall Hebron Univ Hosp & Inst Oncol VHIO, TTD Grp, CIBERONC, Barcelona, Spain
[9] Hosp Univ San Cecilio, Granada, Spain
[10] Hosp Univ Puerta Mar, Cadiz, Spain
[11] Hosp Univ Puerta Hierro, Dept Med Oncol, Madrid, Spain
[12] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
[13] Univ Clin Hosp, Dept Med Oncol, Madrid, Spain
[14] Univ Clin Hosp, Translat Med Oncol Grp, Madrid, Spain
[15] Univ Clin Hosp, Hlth Res Inst IDIS, Madrid, Spain
[16] Univ Santiago Compostela, Sch Med, CIBERONC, Santiago De Compostela, Spain
[17] Hosp Gen Univ Morales Meseguer, Murcia, Spain
[18] Hosp Univ Virgen Ias Nieves, Dept Med Oncol, Granada, Spain
[19] Univ Cordoba, Reina Sofia Hosp, IMIBIC, Inst Salud Carlos III,CIBERONC, Cordoba, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e15556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15556
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    Masuishi, Toshiki
    Moriwaki, Toshikazu
    Fukuoka, Shota
    Takashima, Atsuo
    Kumekawa, Yosuke
    Kajiwara, Takeshi
    Yamazaki, Kentaro
    Esaki, Taito
    Makiyama, Akitaka
    Denda, Tadamichi
    Satake, Hironaga
    Suto, Takeshi
    Sugimoto, Naotoshi
    Katsumata, Kenji
    Ishikawa, Toshiaki
    Kashiwada, Tomomi
    Oki, Eiji
    Komatsu, Yoshito
    Yoshimura, Kenichi
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
    Martinez-Perez, Julia
    Carmen Riesco-Martinez, M.
    Garcia-Carbonero, Rocio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (06) : 643 - 650
  • [23] Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : E181 - E182
  • [24] Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Cutsem, Eric Van
    Elez, Elena
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Liposits, Gabor
    Bondarenko, Igor
    Modest, Dominik P.
    Amellal, Nadia
    Tabernero, Josep
    FUTURE ONCOLOGY, 2024, 20 (36) : 2823 - 2832
  • [25] Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.
    Tabernero, Josep
    Prager, Gerald W.
    Fakih, Marwan
    Ciardiello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe Melo
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik Paul
    Benhadji, Karim A.
    Fougeray, Ronan
    Leger, Catherine
    Amellal, Nadia
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 4 - 4
  • [26] Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    Yuan, Chengbo
    Kurtinecz, Milena
    Pan, Xiaoyun
    Vassilev, Zdravko
    Pisa, Federica
    Ostojic, Helene
    CANCERS, 2025, 17 (06)
  • [27] Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Yoshiaki Fujimoto
    Ryota Nakanishi
    Mamoru Nukatsuka
    Kazuaki Matsuoka
    Koji Ando
    Takeshi Wakasa
    Hiroyuki Kitao
    Eiji Oki
    Yoshihiko Maehara
    Masaki Mori
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 1029 - 1038
  • [28] Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Fujimoto, Yoshiaki
    Nakanishi, Ryota
    Nukatsuka, Mamoru
    Matsuoka, Kazuaki
    Ando, Koji
    Wakasa, Takeshi
    Kitao, Hiroyuki
    Oki, Eiji
    Maehara, Yoshihiko
    Mori, Masaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (06) : 1029 - 1038
  • [29] Treatment outcomes of trifluridine/tipiracil therapy in refractory metastatic colorectal cancer: A single-centre observational study
    Prejac, J.
    Kekez, D.
    Plestina, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S154 - S154
  • [30] Trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer treatment
    Michel, Patryk S.
    Jankowski, Marek
    Sigorski, Dawid
    Kubiatowski, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (06):
12345